[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Syntr Health Technologies, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100479739","evaluating-the-effect-of-adipose-tissue-processed-with-the-syntrfuge-system-for-knee-osteoarthritis-100479739",false,"NCT05526898","Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis","Multi-Center, Randomized Controlled Trial Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis","Inclusion Criteria\n\n* Subjects aged of 35-80 years old\n* Patients with knee osteoarthritis grade II, III, and IV Kellgren-Lawrence\n* Chronic knee pain or symptoms for at least 3 months\n* BMI between 20 and 34.9\n* Willing and able to read and sign the informed consent and other study materials\n* Written informed consent has been obtained prior to any study-related procedures\n* Written Authorization for Use and Release of Health and Research Study Information has been signed\n* Subjects are ambulatory\n* Subject is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study\n* Females of childbearing potential must have a negative urine pregnancy test result and not be lactating\n* Subject is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the Investigator's opinion, exposes the Subject to an unacceptable risk by study participation\n\nExclusion Criteria:\n\n* Subjects with previous traumatic lesion (tibial fracture, osteothomy) of the knee\n* Subjects with osteonecrosis\n* Subjects with meniscal surgery in the previous 6 weeks\n* Subjects with gout, hyperlipidemia\n* Subjects without decisional capacity\n* Subjects with inflammatory arthritis\n* Subjects with active infection\n* Subjects with any uncontrolled systemic disease\n* Subjects with a history of severe allergic\u002Fanaphylactic reactions or multiple allergies\n* Subjects planning to become pregnant, are pregnant, or are breast-feeding\n* Subjects with history or current evidence of drug or alcohol abuse within 36 months prior to screening visit\n* Subjects who have active autoimmune disease\n* Subjects who have coagulation disorders\n* Subjects who have received any other therapy, which, in the opinion of the investigator, could interfere with safety or efficacy evaluations\n* Subjects with current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study\n* Subjects with any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study\n* Subjects who have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time from 7 days pre- to 3 days post injection. A wash out period of 7 days is allowed\n* Subjects who have undergone immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months prior to each study visit.\n* No intra-articular injection of corticosteroids within the last 24 weeks\n* No intra-articular injection of any other cellular therapy within the last 24 weeks",true,"ALL","18 Years","70 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is an multi-center study with the aim of evaluating the efficacy of adipose tissue processed with the SyntrFuge™ system in Orthopedic Surgery, specifically Knee Osteoarthritis. Patients will be enrolled to the treatment group with adipose tissue processed with the SyntrFuge™ system followed by an injection of autologous microsized adipose tissue in the treatment sites or Standard of Care.",[28],"Knee Osteoarthritis",[30,31,32,28,33],"Microsized Fat Tissue","Adipose Tissue","Fat Transfer","Orthopedic Surgery","NOT_YET_RECRUITING","2026-08-19",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":22},"2027-12-01",{"date":42,"type":22},"2030-12",{"name":44,"class":45},"Syntr Health Technologies, Inc.","INDUSTRY",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100479170","randomized-controlled-clinical-investigation-evaluating-the-effect-of-adipose-tissue-processed-with-the-syntrfuge-system-in-the-healing-of-diabetic-foot-ulcers-100479170","NCT05519501","Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot Ulcers","Clinical Investigation Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot Ulcers","Inclusion criteria:\n\n* Subjects who have Diabetic Foot Ulcer located at the pad of the foot or the heel of the foot with a surface area range \\\u003C 1 sq. cm to 25 sq. cm and \\\u003C 5 cm in widest diameter on lower extremity, but larger than 1 sq. cm. Diabetics included will be those with HBA1C ≥ 6.5 % and ≤ 12%\n* Subjects with vascular problems absent or resolved (evaluated with Eco Color Doppler and ABI (Ankle Brachial Index, that calculates the ratio of the systolic pressure measured at the ankle and the systolic pressure in the arm, both measured in supine position using wave continue Doppler. If assessable, it has to be greater than\u002Fequal to .7) and pressure index finger\u002Farm TBI (Toe Brachial Index, if assessable, it has to be greater than\u002Fequal to .6) and\u002For by the determination of the transcutaneous oxygen pressure (TcPO2 that needs to be equal to or greater than 30 mmHg)) or and alternative biphasic and triphasic waveforms, doppler waveform, or DP+PT\n* Subjects are ambulatory\n* Subjects aged 18 - 85\n* All genders\n* All ethnic backgrounds\n\nExclusion criteria:\n\n* Subjects without decisional capacity\n* Subjects unable to give informed, written consent\n* Subjects with active infection (redness, swelling, pain, suppuration)\n* Subjects with osteomyelitis\n* Subjects with a malignancy, burn, collagen vascular disease, sickle cell, vasculopathy, or pyoderma gangrenosum\n* Subjects with active Charcot Arthropathy of the foot\n* Subjects with uncontrolled hyperglycemia (HbA1C \\> 12 %)\n* Subjects with end stage renal disease, creatinine \\> 3.0mg\u002Fdl within 6 months\n* Subjects with previous Rx with NPWT, growth factors, hyperbaric O2, or bioengineered tissue product within 30 days of enrollment\n* Subject has a \\> 30% wound Surface area reduction in size at 2 wk after screening\n* Subjects receiving oncological treatments ongoing or previous (past 5 years) and\u002For neoplastic lesions\n* Subjects under steroid therapy, unless taking dose of 5mg\u002Fdl or less\n* Subjects with any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study","85 Years",{"count":56,"type":22},62,[25],"This is a randomized controlled multi center study on diabetic patients with the aim of evaluating the efficacy of the adipose tissue processed with the SyntrFuge™ system in diabetic patients with diabetic foot ulcers. In particular, it will be evaluated whether the microsized fat graft will be able to shorten the healing times of these wounds. Patients will be randomized to the treatment group with adipose tissue processed with the SyntrFuge™ system (injection of autologous microsized adipose tissue) or to the control group represented by the standard of care.",[60],"Diabetic Foot Ulcer",[30,31,62,63],"DFU","Wound Management",{"date":65,"type":38},"2026-08-21",{"date":67,"type":22},"2026-09-30",{"date":69,"type":22},"2028-06-30",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":46},"100479395","open-label-multi-center-study-evaluating-the-effect-of-adipose-tissue-processed-with-the-syntrfuge-system-for-facial-fat-grafting-100479395","NCT05522426","Open Label, Multi-Center Study, Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Facial Fat Grafting","Inclusion Criteria:\n\n1. Subjects aged of 18-70 years old\n2. Willing and able to read and sign the informed consent and other study materials\n3. Written informed consent has been obtained prior to any study-related procedures\n4. Subjects are ambulatory\n5. Ability to follow study instructions and complete study assessment tools including the subject diary\n6. Females of childbearing potential must have a negative urine pregnancy test result and not be lactating\n7. Agree to not undergo other treatments or cosmetic procedures in the treatment area during the study such as facial laser treatments, botulinum toxin, hyaluronic acid injections, any other permanent or semi-permanent facial fillers\n\n1.5.2 Exclusion Criteria:\n\n1. Subjects without decisional capacity\n2. Subjects unable to give informed, written consent\n3. Subjects with active infection (redness, swelling, pain, suppuration)\n4. Subjects with any uncontrolled systemic disease\n5. Subjects with a history of severe allergic\u002Fanaphylactic reactions or multiple allergies\n6. Subjects with conditions within the treatment area including acne, scarring, acute lupus erythematosus, dermatitis, or melasma\n7. Subjects planning to become pregnant, are pregnant, or are breast-feeding\n8. Subjects with history or current evidence of drug or alcohol abuse within 12 months prior to screening visit\n9. Subjects who have undergone temporary facial dermal filler injections with hyaluronic acid-based fillers within 12 months in the treatment area. Have had neuromodulator injections, mesotherapy, or resurfacing (laser or other ablative or non-ablative procedures) within 5 months prior to entry in the study or be planning to undergo any of these procedures at any time during the study.\n10. Subjects who have undergone facial plastic surgery (except for rhinoplasty or a brow lift), tissue grafting, or tissue augmentation with silicone, fat, or other permanent or semi-permanent dermal fillers or be planning to undergo any of these procedures affecting the treatment area, at any time during the study that may interfere with the study procedure and results\n11. Subjects who have active autoimmune disease\n12. Subjects who are unwilling to undergo fat graft injections\n13. Subjects with current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study\n14. Subjects who have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time from 10 days pre- to 3 days post injection. A wash out period of 10 days is allowed\n15. Subjects who have undergone immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months prior to each study visit.",{"count":78,"type":22},50,[25],"This is an open label multi-center study with the aim of evaluating the efficacy of adipose tissue processed with the SyntrFuge™ system in facial aesthetics and contouring. Patients will be enrolled to the treatment group with adipose tissue processed with the SyntrFuge™ system followed by an injection of autologous microsized adipose tissue in the treatment sites.",[82],"Facial Atrophy and Loss of Contour",[30,31,84,32],"Facial Contouring","2026-08-18",{"date":37,"type":38},{"date":88,"type":22},"2026-09-01",{"date":90,"type":22},"2027-12",{"name":44,"class":45},""]